Skip to main content

Advertisement

Table 3 Comparison of clinical factors with CXCL14 for stage I/II patients and stage III/IV patients

From: Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection

Clinical Factors CXCL14 Expression (stage I/II) CXCL14 Expression (stage III/IV)
  Low (n = 9) High (n = 22) P value Low (n = 68) High (n = 67) P value
Sex    0.599    0.543
Female 27 (29.7%) 10 (11.0%)   34 (25.2%) 37 (27.4%)  
Male 42 (46.2%) 12 (13.2%)   34 (25.2%) 30 (22.2%)  
Age    0.878    0.878
Mean ± SD 62.4 ± 13.5 63.7 ± 14.1   58.7 ± 14.7 59.5 ± 14.0  
Median 65 64   61 62  
Range 25–88 35–82   25–84 29–88  
TNM stage    0.674    0.165
p I 7 (7.7%) 1 (1.1%)     
p II 62 (68.1%) 21 (23.1%)     
p III     66 (48.9%) 61 (45.2%)  
p IV     2 (1.5%) 6 (4.4%)  
Tumor invasion   0.123     0.522
pT1 1 (1.1%) 0 (0%)     
pT2 6 (6.6%) 1 (1.1%)   2 (1.5%) 2 (1.5%)  
pT3 59 (64.8%) 18 (19.8%)   64 (47.4%) 61 (45.2%)  
pT4 3 (3.3%) 3 (3.3%)   2 (1.5%) 4 (3.0%)  
Lymph node No./metastasis   0.348     0.78
0-7/pN0 20 (22.0%) 5 (5.5%)   2 (1.5%) 6 (4.4%)  
8–12/pN1 37 (40.7%) 12 (13.2%)   56 (41.5%) 49 (36.3%)  
>12/pN2 12 (13.2%) 5 (5.5%)   10 (7.4%) 12 (8.9%)  
Grade    0.246    0.05
Well 21 (23.1%) 7 (7.7%)   20 (14.8%) 9 (6.7%)  
Moderate 42 (46.2%) 8 (8.8%)   44 (32.6%) 46 (34.1%)  
Poor 6 (6.6%) 7 (7.7%)   4 (3.0%) 12 (8.9%)  
Tumor size, cm   0.001     0.002
<2 20 (22.0%) 0 (0%)   26 (19.3%) 11 (8.1%)  
2-5 45 (49.5%) 18 (19.8)   34 (25.2%) 38 (28.1%)  
>5 4 (4.4%) 4 (4.4%)   8 (5.9%) 18 (13.3%)  
Location    0.100    0.191
Colon 27 (29.7%) 13 (14.3%)   34 (25.2%) 41 (30.4%)  
Rectum 42 (46.2%) 9 (9.9%)   34 (25.2%) 26 (19.3%)  
  1. Fisher’s exact test; t test; Nonparametric correlations; χ2 test.